Full Text View
Tabular View
Study Results
Related Studies
Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer
This study has been completed.
Study NCT01071915   Information provided by Ferring Pharmaceuticals

First Received on February 18, 2010.   Last Updated on January 8, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostate Cancer
Additional conditions recognized in this trial
Prostatic Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
Degarelix 240/80 mg
Sponsors listed in this trial
Ferring Pharmaceuticals
Ferring Pharmaceuticals Korea, Ltd.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services